Onsite Clinical Solutions, LLC

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Epilepsy6 trials
• Gout2 trials
• Migraine2 trials
• Type 2 diabetes2 trials
• Alzheimer disease1 trial
• Asthma1 trial
• Colorectal cancer1 trial
• Cytomegalovirus infection1 trial
• Diabetic eye disease1 trial
• Gastroparesis1 trial
• Multiple sclerosis1 trial
• Obesity1 trial
• and 2 more

Phase

• Phase 310 trials
• Phase 24 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 41 trial

Status

• Recruiting7 trials
• Completed6 trials
• Active, not recruiting5 trials
• Terminated2 trials

Lead sponsor

• Pfizer4 trials
• Amgen2 trials
• Longboard Pharmaceuticals2 trials
• Xenon Pharmaceuticals Inc.2 trials
• CinDome Pharma, Inc.1 trial
• and 9 more

Running trials

• Recruiting

  A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

  NCT07388498· Phase 3· Amgen· Source

• Recruiting

  Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

  NCT07051629· Phase 1· Suninflam Inc· Source

  Contact: Kenneth Ashkin, MD

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Supernus Pharmaceuticals, Inc.· Source

  Contact: Supernus Clinical Trials

• Recruiting

  An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT06398626· Pfizer· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Active, not recruiting

  A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

  NCT06021522· Phase 3· Emalex Biosciences Inc.· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Xenon Pharmaceuticals Inc.· Source

  Contact: Xenon Medical Affairs

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  NCT04743141· Phase 3· Pfizer· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Pfizer· Source

• Active, not recruiting

  A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

  NCT03811561· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

  NCT02951598· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy3 recruiting
• Migraine2 recruiting
• Gout1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

  NCT06897202· Phase 2· Pfizer· Source

• Completed

  A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

  NCT06229145· Phase 4· Amgen· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

  NCT05832151· Phase 2· CinDome Pharma, Inc.· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

  NCT05626634· Phase 2· Longboard Pharmaceuticals· Source

• Terminated

  Informed Choice - Compass

  NCT05246839· Exact Sciences Corporation· Source

• Completed

  Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

  NCT05364021· Phase 1/2· Longboard Pharmaceuticals· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  NCT05085366· Phase 3· ModernaTX, Inc.· Source